{"page":{"totalFilteredElements":384},"studies":[{"active":true,"description":"Einseitige Implantation des SPIRION Kehlkopfschrittmachers bei Patienten ohne vorherige permanente Glottis-Erweiterung

DRKS00032341

-      Studie mit keiner\nVoroperation am Kehlkopf (ULP)


","eudractNumber":null,"id":8774,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06007170 ","phase":null,"recruitmentStart":"2023-08-18T09:11:34+02:00","shortTitle":"ULP_2022CIP001 Studie mit keiner Voroperation am Kehlkopf","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Effekt von hochdosiertem Vitamin D3 auf die 28-Tages-Mortalität bei erwachsenen kritisch kranken Patienten mit schwerem Vitamin D Mangel: eine multizentrische, Placebo-kontrollierte, doppelblinde Phase III Studie
Eudra-CT: 2016-002460-13
","eudractNumber":"2024-514556-32-00","id":8204,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-03-20T13:38:53+01:00","shortTitle":"VITDALIZE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Beobachtungsstudie zum Einsatz von Venetoclax bei Patienten mit chronisch lymphatischer Leukämie (LCC) unter realen Versorgungsbedingungen","eudractNumber":null,"id":4866,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"},{"name":"BCL (B-cell lymphoma)","id":"mt_202"},{"name":"BCL-2","id":"mt_74"}],"nctNumber":"NCT03342144","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T08:57:14+01:00","shortTitle":"VeRVe","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Verbesserung der Versorgungsqualität durch standardisierte Dokumentation d-uo VERSUS","eudractNumber":null,"id":10722,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-11-11T11:39:37+01:00","shortTitle":"Versus","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":7969,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-06-01T11:21:48+02:00","shortTitle":"WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":9618,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-02-23T10:10:34+01:00","shortTitle":"WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Wirksamkeit\n/ Effekte einer Yogatherapie bei Patienten mit hirneigenem Tumor WHO° Grad III\nund IV und deren Angehörigen

DRKS00029554

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":4430,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2019-02-01T10:00:57+01:00","shortTitle":"YINOTA-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Effekte von Yoga auf Angst, Unruhe, Schlafqualität und Fatigue bei Frauen mit der Erstdiagnose Brustkrebs – eine randomisierte kontrollierte Studie","eudractNumber":null,"id":10894,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-01-01T10:38:07+01:00","shortTitle":"Yoga-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

Molekulare Erregerdiagnostik und Untersuchungen zu\nSARS-CoV-2 bei Patienten mit ZNS-Störung nach hämatopoetischer\nStammzelltransplantation und gesunden Probanden

DRKS00029343 (keine weiteren Registriernummern)

","eudractNumber":null,"id":10388,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-08-16T07:00:05+02:00","shortTitle":"ZNMoDiSZ","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilt-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in combination with Daratumumab SC (Tec-D) Following Induction with Daratumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnose Multiple Myeloma","eudractNumber":"2023-505792-71","id":9857,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-05-08T09:13:35+02:00","shortTitle":"aMMbition","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}